SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001593968-23-000583
Filing Date
2023-04-05
Accepted
2023-04-05 18:43:25
Documents
1
Period of Report
2023-04-01

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_01.html 4  
1 PRIMARY DOCUMENT primary_01.xml 4 3693
  Complete submission text file 0001593968-23-000583.txt   5026
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 210 EAST GRAND AVE SOUTH SAN FRANCISCO CA 94080
Business Address
Smith Lillian (Reporting) CIK: 0001971448 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38693 | Film No.: 23803875